December 22, 2021
A California federal judge kept alive a proposed securities class action Wednesday claiming the biotechnology company Vaxart pumped up its stock price with deceptive headlines about a COVID-19 vaccine, but tossed with leave to amend claims against a hedge fund that sold shares in the wake of Vaxart's statements.
September 30, 2021
U.S. District Judge Vince Chhabria appeared skeptical Thursday of Vaxart's efforts to ditch a proposed securities class action claiming the biotechnology company artificially inflated its stock price with an allegedly deceptive headline about producing a COVID-19 vaccine candidate, saying the defendants "buried the investors in an avalanche of B.S."
May 13, 2021
A group of investors suing Vaxart Inc. can amend their complaint to more clearly allege that the company artificially inflated its stock price through a press release with a deceptive headline about being a COVID-19 vaccine candidate, a California federal judge ruled on Thursday.
March 15, 2021
Vaxart Inc. asked a California federal judge Friday to dismiss allegations that it misled investors about the prospects of its COVID-19 vaccine candidate, saying the securities suit is "premised on statements Vaxart never made."
December 09, 2020
A California federal judge on Wednesday appointed Hagens Berman Sobol Shapiro LLP lead counsel in a proposed class action filed by investors alleging San Francisco-based biotechnology company Vaxart Inc. lied about its COVID-19 vaccine candidate.
November 09, 2020
Investors vying for the lead role in a proposed class action alleging San Francisco-headquartered biotechnology company Vaxart Inc. lied about its COVID-19 vaccine candidate traded jabs in competing responses to each other's pleas to lead the proposed class.
August 24, 2020
Investors in Vaxart Inc. accused the San Francisco-headquartered biotechnology company of lying about its COVID-19 vaccine candidate in order to inflate its stock price, according to a complaint filed Monday in California federal court.